Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Magle Chemoswed Holding AB (publ) has today submitted an application for delisting of the Company's shares from Nasdaq First North Growth Market

MAGLERegulatory press release2026-10-28 09:34
Download the release

The Board of Directors of Magle Chemoswed Holding AB (publ), reg. no. 556913-4710 ("Magle Group" or the "Company"), proposed on 27 July 2026 that the Company's shares be delisted from Nasdaq First North Growth Market. The extraordinary general meeting held on 26 August 2026 resolved, with the required majority, to approve the delisting in accordance with the Board's proposal. The Board has today, on 28 October 2026, submitted an application for voluntary delisting of the Company's shares from Nasdaq First North Growth Market to Nasdaq Stockholm.

Magle Group has requested that the last day of trading in the Company's shares on Nasdaq First North Growth Market be set to 11 November 2026. Magle Group will announce the last day of trading in the Company's shares on Nasdaq First North Growth Market in a separate press release once Nasdaq Stockholm has resolved on the delisting.

Contacts


Aaron Wong, CEO, phone +46 (0)76 664 35 79, aaron.wong@maglegroup.com

About Us


The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. Today, the Group includes two operational areas. Magle Chemoswed – a contract manufacturing organization (CMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle Biopolymers A/S - a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglebiopolymers.com

Redeye Nordic Growth AB is the company's Certified Adviser.

Attachments


Magle Chemoswed Holding AB (publ) has today submitted an application for delisting of the Company's shares from Nasdaq First North Growth Market